



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

March 3, 2020

Via E-mail

Kim C. Drapkin
Chief Financial Officer
Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge, MA 02139

**Re: Jounce Therapeutics, Inc.
Form 10-Q for the Quarterly Period Ended September 30, 2019
Exhibit No. 10.1 - License Agreement by and among the Registrant, Celgene
Corporation, and Celgene RIVOT LLC, dated July 22, 2019
Filed November 7, 2019
File No. 001-37998**

Dear Ms. Drapkin:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance